Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Slides:

Advertisements

Similar presentations

CRC-1 The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer Frances A. Shepherd, MD Scott Taylor Chair in Lung Cancer Research Princess Margaret.

Advertisements

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Nurse View: Management of Pancreatic Cancer

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Evolving Paradigms in Recurrent/Metastatic SCCHN

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

Exploring Early Combination Therapy in PAH

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Advanced NSCLC Without Actionable Mutations

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Does One Size Fit All in Obesity Management?

The Nurse View.

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction to Checkpoint Inhibitors

Spotlight on Immuno-Oncology in Melanoma

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Enhancing Patient Care in Advanced NSCLC Through Clinician-Patient Partnership.

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

More Than Meets the Eye.

Immunotherapy for cSCC

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Patient-Centered Management in Pancreatic Cancer

Best Practices in Lymph Node Mapping and Localization: Melanoma

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Immune Checkpoint Inhibitors in Lung Cancer

The Road to Quality Improvement in HER2-Positive Breast Cancer

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Strengthening Lung Cancer Team Connections to Improve Outcomes With Immunotherapy.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Championing Evidence-Based Care in Patients With Acute Low Back Pain

New Options for the Treatment of Hepatocellular Carcinoma

Next-Generation Sequencing and ctDNA

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

Navigating the Journey

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Updates in Best Practices in Non-Small Cell Lung Cancer

Uncovering the Right Sequence

Presentation transcript:

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer

Overview

Goals of This Program

Case 1

Recommendations for First-Line Treatment of NSCLC

Factors to Consider When Choosing Between Doublet and Triplet Regimens

irAEs

Case 1 (cont)

Recommendations for Patients With NSCLC Who Have Disease Progression

Examples of Potential AEs With Docetaxel-Ramucirumab

Case 1 (cont)

Considerations in Patients With Diarrhea

Case 2

Treatment Considerations

Case 2 (cont)

Treatment Considerations

NCCN Treatment Recommendations

Management of irAEs

Clinical Pearls

Clinical Pearls (cont)

Abbreviations